###begin article-title 0
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP1 </italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP5 </italic>
###xml 368 374 368 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 329 334 <span type="species:ncbi:9606">human</span>
We have previously reported that expression of the Wnt antagonist genes SFRP1 and SFRP5 is frequently silenced by promoter hypermethylation in breast cancer. SFRP2 is a further Wnt inhibitor whose expression was recently found being downregulated in various malignancies. Here we investigated whether SFRP2 is also implicated in human breast cancer, and if so whether SFRP2 promoter methylation might serve as a potential tumor biomarker.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
We analyzed SFRP2 mRNA expression and SFRP2 promoter methylation in 10 breast cell lines, 199 primary breast carcinomas, 20 matched normal breast tissues and 17 cancer-unrelated normal breast tissues using RT-PCR, realtime PCR, methylation-specific PCR and Pyrosequencing, respectively. SFRP2 protein expression was assessed by immunohistochemistry on a tissue microarray. Proliferation assays after transfection with an SFRP2 expression vector were performed with mammary MCF10A cells. Statistical evaluations were accomplished with SPSS 14.0 software.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 750 752 750 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 783 789 783 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 858 860 858 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 622 629 <span type="species:ncbi:9606">patient</span>
###xml 724 731 <span type="species:ncbi:9606">patient</span>
Of the cancerous breast cell lines, 7/8 (88%) lacked SFRP2 mRNA expression due to SFRP2 promoter methylation (P < 0.001). SFRP2 expression was substantially restored in most breast cell lines after treatment with 5-aza-2'-deoxycytidine and trichostatin A. In primary breast carcinomas SFRP2 protein expression was strongly reduced in 93 of 125 specimens (74%). SFRP2 promoter methylation was detected in 165/199 primary carcinomas (83%) whereas all cancer-related and unrelated normal breast tissues were not affected by SFRP2 methylation. SFRP2 methylation was not associated with clinicopathological factors or clinical patient outcome. However, loss of SFRP2 protein expression showed a weak association with unfavorable patient overall survival (P = 0.071). Forced expression of SFRP2 in mammary MCF10A cells substantially inhibited proliferation rates (P = 0.045).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 265 270 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 449 455 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 290 297 <span type="species:ncbi:9606">patient</span>
The SFRP2 gene is a high-frequent target of epigenetic inactivation in human breast cancer. Its methylation leads to abrogation of SFRP2 expression, conferring a growth advantage to epithelial mammary cells. This altogether supports a tumor suppressive function of SFRP2. Although clinical patient outcome was not associated with SFRP2 methylation, the high frequency of this epimutation and its putative specificity to neoplastic cells may qualify SFRP2 promoter methylation as a potential candidate screening marker helping to improve early breast cancer detection.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 157 158 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 438 443 438 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a</sup>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 502 503 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 534 535 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 591 592 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 637 638 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 899 900 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1039 1041 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 166 171 <span type="species:ncbi:9606">human</span>
###xml 993 1000 <span type="species:ncbi:9606">patient</span>
Aberrant promoter methylation leading to functional inactivation of tumor suppressor genes is a well recognized mechanism capable of driving carcinogenesis [1,2]. In human breast cancer numerous genes have been identified with abolished expression due to 5'-cytosine methylation within their gene promoter (recently reviewed in [3]). Typically those genes affect important aspects of normal growth control, like cell cycle regulation (p16INK4a) [4], steroid receptor biology (estrogen receptor-alpha) [5], cell adhesion (E-cadherin) [6], apoptosis (death-associated protein (DAP) kinase-1) [7] or extracellular matrix integrity (ITIH5) [8], all of which confers, in case of expression loss, growth advantages to neoplastic cells. Importantly, the observation that DNA methylation of the same gene may occur both in premalignant lesions, such as atypical hyperplasia of the breast, and in carcinoma [9] suggests that DNA methylation might serve as ideal biomarker for early cancer detection or patient risk assessment in clinical oncology [10]. Thus, identification and validation of epigenetically silenced cancer-related genes is of critical importance in the search of novel tumor biomarkers.
###end p 11
###begin p 12
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 613 615 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 616 618 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 849 851 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 852 854 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 875 881 872 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP1 </italic>
###xml 885 891 882 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP5 </italic>
###xml 1063 1065 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1066 1068 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1071 1077 1068 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1169 1171 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1186 1188 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1200 1202 1197 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1214 1216 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1217 1219 1214 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1229 1231 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1250 1252 1247 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1292 1298 1289 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1452 1458 1449 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1609 1614 1606 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1617 1619 1614 1616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1670 1676 1667 1673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1797 1803 1794 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1874 1876 1871 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1877 1879 1874 1876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1925 1931 1922 1928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 2062 2064 2059 2061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 2065 2067 2062 2064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 430 435 <span type="species:ncbi:9606">human</span>
###xml 834 839 <span type="species:ncbi:9606">human</span>
###xml 1044 1051 <span type="species:ncbi:9606">patient</span>
###xml 1364 1372 <span type="species:ncbi:9606">patients</span>
Secreted frizzled-related proteins (SFRPs) constitute a family of extracellular Wnt signaling antagonists, of which five members (SFRP1-5) have been identified to date [11]. SFRPs sequester Wnt molecules at the cell surface membrane [12] and by this are recognized as sensitive regulators of the canonical Wnt signaling pathway [13]. Aberrant activation of Wnt signaling has been associated with the pathogenesis of virtually all human cancers (reviewed in [14]). In breast tumor tissues, activated Wnt signaling has been repeatedly observed as determined by nuclear and cytoplasmic accumulation of beta-catenin [15-18], arguing for a disrupted equilibrium between Wnt and SFRP expression in this tumor type. In line with this, previous studies have shown that expression of SFRP genes is commonly silenced by promoter methylation in human cancers [19-26]. In breast cancer, SFRP1 and SFRP5 have been identified as targets of aberrant epigenetic inactivation to date, and either promoter methylation was found to be associated with unfavorable patient prognosis [27,28]. SFRP2 has been previously identified as epigenetic target in other tumor entities, such as colon [29], oesophagus [30], bladder [31], stomach [23,24], liver [25] and lung cancer [32]. Interestingly, in all tumor entities SFRP2 methylation was detected with a high frequency of > 50% of cancer patients, ranging from 52% in lung cancer to 96% in gastric cancer, which suggests that SFRP2 methylation might potentially be useful as a ubiquitous pan-tumor marker in cancerous tissues, and possibly also in body fluids. Consequently, Urakami et al. [22] demonstrated that of all investigated SFRPs only SFRP2 methylation proved to be a valuable independent prediction factor for bladder cancer in urine samples. At the same time, SFRP2 methylation was found to occur high-frequent in colon cancer (83-90%) [33,19], which may have forced the establishment of SFRP2 methylation as a promising sensitive screening marker for the stool-based detection of colorectal cancer and premalignant lesions [34-36].
###end p 12
###begin p 13
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 30 32 30 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 332 338 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 675 681 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 774 780 774 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 880 886 880 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1062 1068 1062 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 15 21 <span type="species:ncbi:8164">Suzuki</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 291 298 <span type="species:ncbi:9606">patient</span>
###xml 615 622 <span type="species:ncbi:9606">patient</span>
###xml 843 848 <span type="species:ncbi:9606">human</span>
Very recently, Suzuki et al. [37] reported about SFRP2 methylation in human breast cancer, and their study demonstrated an inhibitory effect of SFRP2 on canonical Wnt signaling in breast cancer cell lines. However, SFRP2 expression analyses in normal and breast carcinoma tissues as well as patient survival analysis in relation to SFRP2 methylation were not addressed. Our approach was to investigate SFRP2 expression and promoter methylation in breast cell lines, primary breast carcinomas and normal breast tissues, followed by comprehensive statistical correlation analysis with clinicopathological factors and patient survival. We also investigated a functional role of SFRP2 in a breast cell line with regard to growth behaviour. In summary, our data confirm that the SFRP2 gene is high-frequently inactivated by promoter methylation in human breast cancer and that loss of SFRP2 expression confers a growth advantage to mammary epithelial cells. In addition, we provide evidence that SFRP2 protein expression is commonly reduced in breast cancer and that SFRP2 methylation might be a potential biomarker useful for early detection of this disease.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Cryoconserved clinical materials
###end title 15
###begin p 16
###xml 1068 1070 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1160 1162 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1247 1249 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1817 1818 1815 1816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 124 131 <span type="species:ncbi:9606">patient</span>
###xml 210 217 <span type="species:ncbi:9606">patient</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
###xml 1260 1268 <span type="species:ncbi:9606">patients</span>
###xml 1773 1780 <span type="species:ncbi:9606">patient</span>
According to a multi-center study design, 20 matched tumor/macroscopically normal samples of breast cancer patients (median patient age: 67 years; range 48-86 years) and 179 unmatched breast carcinomas (median patient age: 57 years; range 28-96 years) were obtained from patients treated by primary surgery for breast cancer at the Departments of Gynecology at the University Hospitals of Aachen, Jena, Regensburg and Dusseldorf, Germany. None of the patients had received neo-adjuvant chemotherapy. Inclusion criterion for ipsilateral normal breast tissue was a distance of > 2 cm to the carcinoma margin. All patients gave informed consent for retention and analysis of their tissue for research purposes and the Institutional Review Boards of the participating centers approved the study. The selection of cases was based on availability of tissue. Cases were not stratified for any known preoperative or pathological prognostic factor. Tumor histology was determined according to the criteria of the WHO (2003), while disease stage was assessed according to UICC [38]. Tumors were graded according to Bloom and Richardson, as modified by Elston and Ellis [39]. Hormone receptor positivity was defined as an immunoreactivity score (IRS) >/= 3 [40]. For 136 patients follow-up data were available with a median time of 64 months (range 1-174 months). Tumor material was immediately snap-frozen in liquid nitrogen after surgery. Hematoxylin/Eosin-stained sections were prepared for assessing the percentage of tumor cells; only samples with greater than 70% tumor cells were selected for analysis. Samples were dissolved in lysis buffer followed by DNA isolation using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. For patient characteristics see additional file 1.
###end p 16
###begin title 17
Formalin-fixed, paraffin-embedded (FFPE) clinical material
###end title 17
###begin p 18
###xml 152 160 <span type="species:ncbi:9606">patients</span>
A total of 17 archival FFPE normal breast tissues were obtained from the Institute of Pathology, University Hospital of the RWTH Aachen, Germany. These patients had undergone breast reduction surgery without the condition of cancer. The median age in the cancer-unrelated normal breast tissue set was 33 years (range 22-61 years). Per sample, five consecutive sections (each 10 mum) were deparaffinized and rehydrated in a decreasing alcohol series prior to DNA extraction by use of the QIAamp DNA Mini Kit.
###end p 18
###begin p 19
###xml 130 138 130 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
SFRP2 protein expression was assessed using a tissue microarray (TMA) consisting of 125 breast carcinomas, four ductal carcinomas in situ (DCIS) and 10 normal breast tissues that have been described previously [41]. The TMA contained one tissue core from non-selected, FFPE primary breast carcinoma specimens diagnosed between 1994 and 2002 at the Institute of Pathology, University of Regensburg, Germany. Histological, all tumors were graded according to Bloom and Richardson, as modified by Elston and Ellis [39]. Clinical follow-up data were available for 124 breast cancer patients with a median follow-up period of 80 months (range 5-114 months). All patients gave informed consent for retention and analysis of their tissue for research purposes and the Institutional Review Board of the participating centers approved the study.
###end p 19
###begin title 20
Immunohistochemistry
###end title 20
###begin p 21
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 857 860 857 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 869 874 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 877 879 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 305 311 <span type="species:ncbi:9986">rabbit</span>
The TMA was subjected to immunostaining using the K5007 Kit (DAKO, Hamburg, Germany) following the manufacturer's instructions. Antigen retrieval was performed by pretreatment in citrate buffer (pH 7) in a microwave oven (20 min, 200 W). Samples were incubated for 30 min with the primary SFRP2 antibody (rabbit polyclonal IgG; H-140; 1:75; Santa Cruz Biotechnology, Santa Cruz, CA), washed, and incubated for 10 min with the secondary antibody (biotinylated polylink; DAKO). Diaminobenzidin (DAKO) was used for antibody detection. In negative controls the primary antibody was omitted. An experienced breast cancer pathologist (N.B.) scored the immunohistochemical staining according to the scoring system suggested by Remmele and Stegner [40]. Feasibility of the antibody for immunohistochemical analysis of breast tissue has been previously demonstrated e.g. by Lee et al. [42].
###end p 21
###begin title 22
Cell lines
###end title 22
###begin p 23
The benign cell lines HMEC and MCF10A as well as the cancerous breast cell lines BT20, BT474, Hs578T, MCF7, MDA-MB-231, MDA-MB-453, SKBR3, T47D and ZR75-1 were obtained from the American Type Culture Collection (Rockville, MA) and cultured as recommended by the vendor.
###end p 23
###begin title 24
Reverse transcription (RT-) PCR and semi-quantitative realtime PCR
###end title 24
###begin p 25
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
RNA isolation, RT-PCR and SYBR Green I realtime PCR (Roche Diagnostics, Mannheim, Germany) were performed as described elsewhere [27]. Quality of cDNA was checked after each preparation by standard RT-PCR using glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) primers that yield an amplification product of 510 bp. To ensure experiment accuracy, all quantitative measurements were performed in triplicate. Intron-spanning primer sequences and cycle conditions are given in additional file 2.
###end p 25
###begin title 26
Sodium bisulfite-modification and methylation-specific PCR (MSP)
###end title 26
###begin p 27
###xml 309 310 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 922 928 919 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 987 989 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1261 1265 1245 1249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1598 1600 1552 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
Of the genomic DNA, 1 mug was bisulfite-modified using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer's recommendations. The final precipitate was eluted in 20 mul TRIS buffer (10 mM). For MSP, one mul of modified DNA was amplified using MSP primers (see additional file 2) that specifically recognized either the unmethylated or methylated gene promoter sequence after bisulfite-conversion. Each primer pair mapped to nine cytosine-phosphate-guanine dinucleotide (CpG) sites in order to specifically discriminate between methylated and non-methylated DNA. Further 11 non-CpG cytosines within the primer pair specific for methylated DNA and 13 non-CpG cytosines within the primer pair specific for non-methylated DNA guaranteed unequivocal amplification of bisulfite-converted DNA. Primers defined an amplicon between +19 and +163 relative to the transcription start site (+1) of the SFRP2 gene. Reaction volumes of 25 mul contained 1 x MSP-buffer [44], 400 nM each of methylation and non-methylation-specific primers, respectively, and 1.25 mM of dNTPs. One drop of mineral oil was added to the reaction tube. The PCR was initiated as "Hot Start" PCR at 94degreesC and held at 80degreesC before the addition of 1.25 units Taq DNA polymerase (Promega, Madison, WI). Cycle conditions were: 95degreesC for 5 min, 35 cycles of 95degreesC for 30 s, 60degreesC for 30 s, 72degreesC for 40 s and a final extension at 72degreesC for 5 min. Blood lymphocyte DNA from a healthy donor was bisulfite-modified to serve as a control for the unmethylated promoter sequence [45], DNA from the cancerous breast cell line BT20 served as control for methylated alleles. Amplification products were visualized on 3% low range ultra agarose gel (Bio-Rad Laboratories, Hercules, CA) containing ethidium bromide and illuminated under ultraviolet (UV) light.
###end p 27
###begin title 28
Pyrosequencing
###end title 28
###begin p 29
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 215 221 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 552 556 551 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 576 580 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 616 617 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 819 823 805 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1778 1784 1732 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Quantitative Pyrosequencing of a SFRP2 promoter fragment was performed by use of a Pyromark ID device, PyroGoldSQA Reagent Kit and Pyro Q-CpG software (Biotage, Uppsala, Sweden). Initially, a 291 bp fragment of the SFRP2 promoter (relative position -28 to +263), covering the hybridization sites for MSP primers, was amplified with degenerate primers irrespective of the methylation status, which assures unbiased DNA amplification. To enable single strand preparation the reverse primer was 5'-biotinylated. Reaction volumes of 50 mul contained 1 x GoTaq buffer, 2.5 units GoTaq polymerase (Promega), 2.5 mM of MgCl2, 400 nM of primers, 500 nM of each dNTP, and 3 mul of bisulfite-converted DNA as template. Reactions were initiated as "Hot Start" PCR at 95degreesC for 3 min and held at 80degreesC before addition of Taq polymerase. Cycle conditions were: 94degreesC for 3 min, 50 cycles of 94degreesC for 15 sec, 58degreesC for 30 sec, 72degreesC for 30 sec, and a final extension step at 72degreesC for 5 min. PCR was carried out in a PTC-200 cycler (Bio-Rad, formerly MJ Research, Hercules, CA). Prior to sequencing, aliquots of the amplificate were analyzed on a 2% agarose gel containing ethidium bromide under UV light. Single strand separation of the remaining amplificate (40 mul) was performed with a PyroMark Vacuum Prep Workstation (Biotage). Amplificate was immobilized to Streptavidin-Sepharose HP beads (Amersham Biosciences, Uppsala, Sweden), washed, denatured and the biotinylated strands were released into 40 mul of annealing buffer containing 400 nM of forward sequencing primer. Sequencing started with position +3 (relative to the TSS) and was continued to position +167, covering a total of 22 sequential CpG sites. The following sequence represents the SFRP2 promoter sequence that was analyzed by pyrosequencing: AYGGTTTATTTTGTTTTTTYGGGTYGGAGT TTTTYGGAGTTGYGYGYGGGTT TGTAGTGTTTYGTTYGYGTTGTTTTTTYGGTGTTTYGTTTTTTYGYGTT TTAGTYGTYGGTTGTT AGTTTTTYGGGGTTTYGAGTYGTATTTAGYGAAGAGAGYGGGTTYGG.
###end p 29
###begin p 30
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Universal bisulfite-converted polymethylated and unmethylated DNA (Epi Tect Control DNA Set; Qiagen, Hilden, Germany) served as technical controls for SFRP2 methylation and non-methylation, respectively. Pyrosequencing primers are available on request.
###end p 30
###begin title 31
5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA) treatment
###end title 31
###begin p 32
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
We plated cells at 3 x 104 cells/cm2 in a six-well plate on day 0. The demethylating agent DAC (Sigma-Aldrich, Deisenheim, Germany) was added to a final concentration of 1 muM in fresh medium on days 1, 2 and 3. Additionally, 300 nM TSA (Sigma-Aldrich) was added on day 3. Cells were harvested on day 4 for RNA and DNA extraction. Control cells were incubated without the addition of DAC or TSA and fresh medium was also supplied on days 1, 2 and 3.
###end p 32
###begin title 33
Transient transfection
###end title 33
###begin p 34
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 50 52 50 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 108 110 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 323 327 323 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1</italic>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 374 379 374 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1 </italic>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Cells were seeded at a density of 3 x 104 cells/cm2 and transfected 24 hours after incubation with 100 ng/cm2 of plasmid DNA in the following manner: 100 ng of empty pCMV-hemagglutinin (HA) vector control (Clontech, Heidelberg, Germany), or 50 ng of pCMV-HA + 50 ng pCMV-HA/SFRP2, or 50 ng of pCMV-HA + 50 ng pcDNA3.1-HisA/WNT1, or 50 ng pCMV-HA/SFRP2 + 50 ng pcDNA3.1-HisA/WNT1 [19] applying the FuGENE 6 transfection system (Roche Diagnostics) and a 3:1 transfection ratio according to the manufacturer's instructions.
###end p 34
###begin title 35
Proliferation assays
###end title 35
###begin p 36
MCF10A cells were transfected in 96-well plates as described above and an XTT-proliferation assay (Roche Diagnostics) was performed on day 0, 1, 2 and 3 after transfection by determining the optical density of the supernatants at 480 nm minus the optical density of the supernatants at 690 nm. To enhance experimental accuracy, six replicas were seeded. For the colony formation assay cells were transfected accordingly in six-well plates and kept for three weeks under selective force of the antibiotic G418 (700 mug/ml) (Invitrogen, Carlsbad, CA). After incubation, colonies were washed with phosphate-buffered saline, fixed and stained for 30 minutes (0.25% crystal violet in 10% formalin/80% methanol), washed three times with distilled water and photographed.
###end p 36
###begin title 37
Statistical methods
###end title 37
###begin p 38
###xml 153 154 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 499 505 499 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 879 887 <span type="species:ncbi:9606">patients</span>
###xml 1176 1184 <span type="species:ncbi:9606">patients</span>
Statistical analyses were completed using the software package SPSS, version 14.0 (SPSS Inc., Chicago, IL). Differences were considered significant when P-values were below 0.05. A two-sided non-parametric Mann-Whitney U-test and a paired student's t-test were performed to analyze differences in expression levels. Associations between metrical variables were determined by a linear regression analysis. To study statistical associations between clinicopathological factors and SFRP2 expression or SFRP2 promoter methylation status contingency-tables and two-sided Fisher's exact tests were accomplished. Survival curves were calculated using the Kaplan-Meier method, with significance evaluated by two-sided log-rank statistics. Overall survival (OS) (n = 136 for MSP samples) was measured from the day of surgery until tumor-related death (20.6%, n = 28) and was censored for patients alive at last contact (69.1%, n = 94), in case of death unrelated to the tumor (3.7%, n = 5) or when the death cause was unknown (6.6%, n = 9). Disease-free survival (DFS) (n = 136 for MSP samples) was measured from surgery until local or distant relapse (36.8%, n = 50) and censored for patients alive without evidence of relapse at the last follow-up (63.2%, n = 86).
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Expression of SFRP2 mRNA is reduced in breast cancer cell lines
###end title 40
###begin p 41
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 598 604 598 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 539 544 <span type="species:ncbi:9606">human</span>
Initiating our analysis, we used the RT-PCR technique to evaluate whether SFRP2 mRNA is differentially expressed in human breast cell lines. SFRP2 mRNA expression was detectable in the benign cell line HMEC, whilst its expression was absent in the cancerous cell lines MDA-MB-231, MCF7, SKBR3, T47D, MDA-MB-453, BT20 and BT474 (Figure 1A). Of the cancerous cell lines only Hs578T exhibited strong SFRP2 expression. However, SFRP2 expression was also absent in the benign cell line MCF10A. Additionally, in a commercially available cDNA of human normal breast tissue (Clontech, Heidelberg, Germany) SFRP2 was strongly expressed while its expression was substantially reduced in Clontech's cDNA of primary breast carcinoma.
###end p 41
###begin p 42
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>SFRP2 </italic>expression and promoter methylation in breast cancer cell lines</bold>
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 585 591 585 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 692 698 692 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1266 1272 1266 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1550 1556 1550 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1615 1621 1615 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1767 1773 1767 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1786 1792 1786 1792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 381 386 <span type="species:ncbi:9606">human</span>
###xml 519 524 <span type="species:ncbi:9606">human</span>
###xml 579 584 <span type="species:ncbi:9606">human</span>
SFRP2 expression and promoter methylation in breast cancer cell lines. (A) SFRP2 mRNA expression in benign and malignant cell lines was determined by RT-PCR. All but one malignant cell line (Hs578T) completely lacked SFRP2 mRNA expression. Of the two benign breast cell lines (MCF10A and HMEC) only HMEC cells were found to express abundant SFRP2 mRNA. In a commercially available human normal breast tissue cDNA SFRP2 expression was clearly detectable, while expression was strongly reduced in a corresponding cDNA of human malignant breast tissue. (B) Genomic structure of the human SFRP2 gene on chromosome 4q31. Bioinformatic analysis revealed three CGIs (light blue), located within the SFRP2 promoter (left CGI), the 5' untranslated region (UTR; central CGI) and the coding sequence (CDS; right CGI). Methylation of the central CGI was explored by MSP. Circles indicate CpG sites; filled circles represent MSP forward (MSP-F) and reverse (MSP-R) primer hybridization sites. Indicated positions are related to the transcription start site (+1) initiating the 5'-UTR. (C) MSP was performed with bisulfite-treated DNA from the same breast cell lines as in A. DNA bands in lanes labeled with U indicate PCR products amplified with primers recognizing unmethylated SFRP2 promoter sequence. DNA bands in lanes labeled with M represent amplification products with methylation-specific primers. Five out of eight mammary tumor cell lines exhibit complete promoter methylation (MDA-MB-231, MCF7, MDA-MB-453, BT20 and BT474), two cell lines show partial SFRP2 methylation (SKBR3 and T47D). In Hs578T, only unmethylated SFRP2 promoter sequence could be detected, like it was also found in benign HMEC cells. In addition, lymphocyte DNA from a healthy donor did not reveal SFRP2 methylation. GAPDH served as cDNA loading control; NTC represents the no template control.
###end p 42
###begin title 43
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Methylation of the SFRP2 promoter in breast cancer cell lines
###end title 43
###begin p 44
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 536 542 536 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 797 802 797 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 848 854 848 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1037 1043 1037 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1348 1354 1348 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1473 1479 1473 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1547 1553 1547 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1596 1602 1596 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 790 796 <span type="species:ncbi:8164">Suzuki</span>
Analysis of the SFRP2 gene promoter on chromosome 4q31 [46] using the genomic DNA information contained in Ensembl contig ENSG00000145423 [47] revealed a CpG island (CGI) between base position -818 to +743 relative to the expected transcription start site (+1), according to the CGI definition of Takai and Jones [48]. Further exploration of this CGI using Methprimer software [49] identified three regions of particularly high CpG density (-399 to -151, -6 to +332, and +486 to +685) (Figure 1B). Since sequence integrity of the first SFRP2 exon was demonstrated to be most essential for efficient RNA transcription in a luciferase promoter assay [24] we chose the central CGI (-6 to +332) for subsequent methylation analysis by application of the highly specific MSP primers described by Suzuki et al. [29] and others [24,37]. First, we assessed SFRP2 promoter methylation in eight cancerous and two non-cancerous cell lines. Six of the analyzed cell lines (MCF10A, MDA-MB-231, MCF7, MDA-MB-453, BT20 and BT474) exhibited a methylated SFRP2 promoter sequence in the analyzed region (Figure 1C). Two cell lines (SKBR3 and T47D) showed partial promoter methylation, since a mixture of unmethylated and methylated DNA sequence could be detected in the same sample. One malignant cell line (Hs578T) and benign HMEC cells revealed solely unmethylated SFRP2 promoter sequence. This result correlates with the above described finding that Hs578T and HMEC cells exhibited strong SFRP2 mRNA expression whereas in all cell lines with aberrant methylation SFRP2 mRNA expression was absent. Interestingly, SFRP2 mRNA was not expressed at detectable levels from unmethyated alleles in SKBR3 and T47D, which may be due to repressing mechanisms that are codominant to the effect of promoter methylation in these cells.
###end p 44
###begin title 45
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 34 43 34 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Re-expression of SFRP2 mRNA after in vitro DNA demethylation
###end title 45
###begin p 46
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 362 364 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 475 481 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 797 803 796 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 827 829 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 883 889 881 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 963 969 961 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1076 1082 1074 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
We next asked whether SFRP2 promoter methylation is functionally associated with loss of SFRP2 mRNA expression in breast cell lines. To address this question we treated four representative breast cancer cell lines for four days with 1 muM of the methyltransferase inhibitor DAC and one day with 300 nM of the histone deacetylase inhibitor TSA. As seen in Figure 2A, in three cell lines (BT20, MCF7 and T47D) the DAC/TSA treatment resulted in a clear increase of unmethylated SFRP2 promoter sequence, only in SKBR3 cells there was no visible difference detectable. Interestingly, BT20 and MCF7 showed demethylation after the addition of DAC alone, whereas in T47D cells such effect was only achieved by the combination of DAC and TSA. Before the treatment, none of the cell lines showed detectable SFRP2 mRNA expression (Figure 2B). The treatment with 1 muM DAC alone did not reverse SFRP2 gene repression in these cells. TSA, in contrast, was able to induce some SFRP2 expression in SKBR3 and T47D cells. Importantly, only the combination of both drugs substantially restored SFRP2 mRNA expression in all analyzed cell lines.
###end p 46
###begin p 47
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Global demethylation and histone acetylation restores <italic>SFRP2 </italic>expression</bold>
###xml 423 429 422 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 578 584 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 612 618 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 811 817 809 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 965 971 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1085 1091 1083 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1126 1132 1124 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 1443 1445 1441 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1539 1545 1537 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
Global demethylation and histone acetylation restores SFRP2 expression. (A) MSP of four malignant cell lines was performed with DNA from either untreated cells, or after treatment with 1 muM DAC, or after treatment with 300 nM TSA, or after a combined treatment applying both drugs. In three cell lines (BT20, MCF7, T47D) a promoter demethylating effect could be visually detected, since signals indicative of unmethylated SFRP2 promoter arise (BT20, MCF7) or become enhanced (T47D) after the combined treatment. In T47D, DAC alone had no detectable demethylating effect on the SFRP2 promoter. (B) Expression of SFRP2 mRNA before treatment, or after treatment with 1 muM DAC, or after treatment with 300 nM TSA, or after a combined treatment applying both drugs. Treatment with DAC alone was not able to induce SFRP2 expression in all cell lines, in contrast to TSA which induced expression in two out of four cell lines (SKBR3 and T47D) previously showing partial SFRP2 methylation. However, only combined promoter demethylation and histone reacetylation leads to strong induction of SFRP2 mRNA expression in all cell lines. GAPDH served as cDNA loading control. (C) Suppression of Cyclin D1 mRNA expression after global DNA demethylation of breast cancer cell lines as determined by realtime PCR. Untreated tumor cells (black bars) and cells treated with DAC/TSA (grey bars) show significantly different expression levels of Cyclin D1 mRNA (P = 0.029, two-sided Mann-Whitney U-test). Expression level of each sample is normalized to its GAPDH expression and related to untreated BT20 cells (set to 1).
###end p 47
###begin p 48
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 396 398 396 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
To further prove that the demethylating treatment did not result in unspecific upregulation of gene expression, we determined the expression of the growth promoting gene cyclin D1, which is a direct read-out gene of active Wnt signaling [50] and whose expression is commonly elevated in breast cancer [51]. Using realtime PCR we observed that cyclin D1 mRNA expression was significantly reduced (P = 0.029, two-tailed Mann-Whitney U-test) after the demethylation treatment (43-fold in BT20, 14-fold in SKBR3, 8-fold in T47D and 6-fold in MCF7, Figure 2C), suggesting that inhibitors of proliferation, such as SFRPs which are downregulated in breast cancer cell lines, have been reactivated and were able to block Wnt signaling in these cells.
###end p 48
###begin title 49
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Methylation of the SFRP2 promoter in primary breast carcinoma and normal breast tissue
###end title 49
###begin p 50
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 473 476 473 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 662 665 662 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 767 770 767 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 786 787 786 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 981 986 981 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1018 1024 1018 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1196 1199 1196 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 1208 1209 1208 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1231 1237 1231 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 974 980 <span type="species:ncbi:8164">Suzuki</span>
In order to answer the question whether SFRP2 promoter methylation occurs in primary breast carcinoma as well we analyzed 199 mammary tumor samples by MSP. For 20 breast tumors corresponding tissues of histological normal breast epithelium were available and analyzed in parallel. Representative results are shown in Figure 3. In total, 165 of 199 tumor samples (83%) showed SFRP2 promoter methylation as a PCR product could be amplified with methylation-specific primers (e.g. #103 in Figure 3), and 34 of 199 tumors (17%) showed no evidence of promoter methylation since exclusive amplification signals were obtained with primers specific to unmethylated DNA (e.g. #108 in Figure 3). None of the 20 matched normal breast tissue samples showed a methylation signal (e.g. #03 in Figure 3). Tumor samples generally exhibited also unmethylated promoter sequences due to possible contamination with small amounts of stromal and endothelial cells, as has also been described by Suzuki et al. [19]. To further confirm that SFRP2 promoter methylation in breast cancer is restricted to malignant tissue, we analyzed 17 cancer-unrelated normal breast samples. Again, none of these normal breast tissues (e.g. Figure 3) harbored detectable SFRP2 methylation.
###end p 50
###begin p 51
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>SFRP2 </italic>methylation analysis of primary breast cancer specimens</bold>
###xml 321 327 321 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 186 193 <span type="species:ncbi:9606">patient</span>
SFRP2 methylation analysis of primary breast cancer specimens. MSP was performed on bisulfite-treated DNA from primary invasive breast cancer tissues. MSP results from 19 representative patient samples are shown. DNA bands in lanes labeled with U indicate PCR products amplified with primers recognizing the unmethylated SFRP2 promoter sequence. DNA bands in lanes labeled with M represent amplified products with methylation-specific primers. In addition, five representative normal cancer-unrelated breast tissues (N1 - N5) are shown. DNA from the breast cancer cell line BT20 and lymphocyte DNA from a healthy donor (Lyc) served as positive controls for MSP. NTC designates the no template control; T indicates tumor tissue; N indicates normal breast tissue.
###end p 51
###begin title 52
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Correlation of SFRP2 promoter methylation and SFRP2 mRNA expression in breast cancer cell lines
###end title 52
###begin p 53
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 506 512 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 552 553 548 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 555 560 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 561 567 557 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 582 584 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 607 613 603 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 647 650 643 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 728 734 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 757 759 749 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 759 764 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 765 771 757 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 787 793 779 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 931 936 923 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 957 962 949 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 1020 1026 1012 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1065 1071 1057 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1088 1090 1080 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1106 1108 1098 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 1182 1188 1174 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1255 1261 1247 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
In order to investigate the association of SFRP2 promoter methylation with transcriptional silencing in a quantitative manner we assessed in parallel SFRP2 mRNA expression by realtime PCR and SFRP2 methylation by quantitative Pyrosequencing in breast cell lines. The technical controls for Pyrosequencing revealed median methylation of 4% (unmethylated control) and 90% (methylated control) in the 22 sequential CpG sites, by this defining the detection limits of this assay. HMEC cells exhibited abundant SFRP2 mRNA expression (Deltacycle threshold (CT) GAPDH:SFRP2 = 5.1) (Figure 4A) together with median SFRP2 methylation of 4%, in contrast to e.g. BT20 cells which exhibited mean methylation of 83% together with absence of SFRP2 mRNA expression (DeltaCT GAPDH:SFRP2 = 19.9). Median SFRP2 methylation for Hs578T, MCF10A, MCF7, MDA-MB-231, SKBR3 and T47D was 5%, 73%, 73%, 71%, 61% and 42%, respectively. A direct comparison of SFRP2 mRNA expression and SFRP2 promoter methylation indicates that in breast cell lines SFRP2 methylation is correlated with loss of SFRP2 mRNA expression (P < 0.001; Figure 4B). Thus, when applying an empiric cut-off of > 5% to discriminate between SFRP2 methylation and non-methylation, all semi-quantitative results for SFRP2 methylation in breast cell lines obtained by MSP could be confirmed by the quantitative Pyrosequencing assay.
###end p 53
###begin p 54
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Correlation of <italic>SFRP2 </italic>promoter methylation and loss of <italic>SFRP2 </italic>mRNA expression in breast cell lines</bold>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 377 383 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 451 457 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 562 568 562 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 590 592 590 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Correlation of SFRP2 promoter methylation and loss of SFRP2 mRNA expression in breast cell lines. (A) Realtime PCR of eight breast cell lines revealed abundant SFRP2 mRNA expression in benign HMEC and malignant Hs578T cells (green bars), whereas in all other investigated malignant breast cell lines SFRP2 mRNA expression was substantially reduced (grey bars). (B) Plotting of SFRP2 mRNA expression from the same cell lines (Y-axis) against each mean SFRP2 promoter methylation value (X-axis) reveals a significant correlation between loss of RNA expression and SFRP2 promoter methylation (P = 0.001; Pearson's correlation coefficient r = -0.9241).
###end p 54
###begin title 55
Differential expression of SFRP2 protein in primary breast cancer
###end title 55
###begin p 56
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 439 441 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 855 860 849 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D, E</xref>
###xml 1203 1208 1193 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5F, G</xref>
###xml 1315 1317 1305 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Immunohistochemical analysis was used to investigate SFRP2 protein expression in normal and malignant breast tissue. A total of 125 informative breast cancer cases, four DCIS and 10 normal breast tissues were analyzed. Intensity of immunohistochemical staining was evaluated using a semi-quantitative IRS [39]. SFRP2 protein was clearly detectable in 90% (9/10) of normal breast tissue samples analyzed, as defined by an IRS >/= 8 (Figure 5C). The mean expression was determined to be IRS = 7.5 (range 3-8; standard deviation (SD) +/- 1.6), and median expression to be IRS = 8. Expression was predominantly localized in luminal and basal epithelial cells of the normal breast while weak expression was detectable in adjacent stromal cells. In four DCIS, SFRP2 expression was slightly reduced (mean IRS = 6.5; range 4-8; SD +/- 1.9; median IRS = 7; Figure 5D, E) with one sample showing strong reduction (25%, IRS = 4). However, the mean expression in invasive breast carcinomas was determined to be IRS = 4.6 (range 0-8; SD +/- 2.1) and median expression to be IRS = 4. Invasive breast carcinomas showed strongly reduced or complete loss (IRS </= 4) of SFRP2 expression in 74% (93/125) of cases (Figure 5F, G). The SFRP2 expression difference between tumors and normal breast tissues was statistically significant (P = 0.001).
###end p 56
###begin p 57
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 protein expression in normal and malignant breast tissues</bold>
###xml 451 459 451 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
SFRP2 protein expression in normal and malignant breast tissues. (A) In the negative control showing normal breast tissue the primary SFRP2 antibody was omitted. (B) Scale-up of negative control shown in A. (C) Strong SFRP2 expression in ducts and lobules of normal breast tissue (IRS = 12). SFRP2 expression is abundant in epithelial cells, while there is only weak expression in stromal cells. (D) Very abundant SFRP2 expression in ductal carcinoma in situ of the breast. (E) Scale-up of specimen shown in D. (F) High-grade tumor exhibiting substantial loss of SFRP2 expression (IRS = 0). (G) Scale-up of specimen shown in F. (H) High-grade breast carcinoma with intensive cytoplasmic SFRP2 staining (IRS = 12). Original magnifications: A, F = 100x; B, C, G, H = 200x; D = 40x; E = 400x.
###end p 57
###begin title 58
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 94 101 <span type="species:ncbi:9606">patient</span>
Correlation of SFRP2 expression and SFRP2 methylation with clinicopathological parameters and patient survival
###end title 58
###begin p 59
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 466 468 464 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 593 595 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 655 657 653 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 674 675 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 678 684 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 886 887 884 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1109 1110 1107 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1122 1128 1120 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1173 1175 1171 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1207 1209 1205 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Clinicopathological characteristics of breast cancer patients were first correlated with SFRP2 protein expression for descriptive data analysis (Table 1). Loss of SFRP2 expression in tumor tissue (IRS </= 4) was not associated with age at diagnosis, tumor size, histological grade, histological type, estrogen/progesterone receptor status, Her2 status or expression of p53. A prevalence of more abundant SFRP2 expression was detected in node negative breast tumors (P = 0.033). In univariate survival analysis using log-rank test, loss of SFRP2 protein expression was not associated with DFS (P = 0.237), but a weak trend was detected towards reduced OS (P = 0.071) (Figure 6). SFRP2 promoter methylation in breast carcinomas was not associated with age at diagnosis, tumor size, lymph node status, histological grade, histological type, or estrogen/progesterone receptor status (Table 2). In univariate survival analysis, lymph node status, histological grade and histological type were significantly associated with DFS; lymph node status and histological grade were significantly associated with OS (Table 3). However, SFRP2 methylation was neither associated with DFS (P = 0.192) nor with OS intervals (P = 0.686).
###end p 59
###begin p 60
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Loss of SFRP2 protein expression in correlation to patient survival</bold>
###xml 336 338 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 589 591 587 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 51 58 <span type="species:ncbi:9606">patient</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
###xml 433 440 <span type="species:ncbi:9606">patient</span>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
Loss of SFRP2 protein expression in correlation to patient survival. (A) Univariate Kaplan-Meier analysis of patient overall survival stratified between SFRP2 expresser (IRS > 4, blue line) and SFRP2 non-expresser (IRS </= 4, red line). A weak association of loss of SFRP2 protein expression with unfavorable outcome could be detected (P = 0.071, two-sided log-rank test). (B) Univariate Kaplan-Meier analysis regarding disease-free patient survival. The visual impression of a clinical impact of SFRP2 protein expression loss on breast tumor recurrence was statistically not significant (P = 0.237, two-sided log-rank test). Vertical tick marks represent censored patients.
###end p 60
###begin p 61
Clinicopathological and immunohistochemical factors in relation to SFRP2 immunoreactivity
###end p 61
###begin p 62
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 152 153 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 257 258 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary, unilateral, invasive breast cancer were included. bAccording to UICC: TNM Classification of Malignant Tumours [38]. cIRS = immunoreactivity score according to Remmele and Stegner [40]. dPearson's correlation coefficient. eFisher's exact test (two-sided). Significant P-values are marked in bold face. Percentages may not sum to 100 due to rounding.
###end p 62
###begin p 63
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 100 107 <span type="species:ncbi:9606">patient</span>
Correlation analysis of SFRP2 promoter methylation with clinicopathological and immunohistochemical patient characteristics
###end p 63
###begin p 64
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 122 123 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 156 157 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary, unilateral, invasive breast cancer were included. bPearson's correlation coefficient. cFisher's exact test (two-sided). dAccording to UICC: TNM Classification of Malignant Tumours [38]. eIRS = immunoreactivity score [40]. Significant P-values marked in bold face.
###end p 64
###begin p 65
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Univariate survival analysis of clinicopathological and immunohistochemical parameters with SFRP2 promoter methylation
###end p 65
###begin p 66
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
aOnly female patients with primary, unilateral, invasive breast cancer were included. bUnivariate log-rank test (two-sided). cAccording to UICC: TNM Classification of Malignant Tumours [38]. dIRS = immunoreactivity score [40]. Significant P-values marked in bold face.
###end p 66
###begin title 67
SFRP2 inhibits proliferation in breast cell lines
###end title 67
###begin p 68
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1 </italic>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1 </italic>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 956 961 956 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 1155 1157 1155 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Finally, we asked whether SFRP2 influences proliferation rates in breast cell lines. For gain-of-function experiments we chose mammary MCF10A cells since these cells were found to lack SFRP2 mRNA expression. As shown in Figure 7A, WNT1 overexpressing MCF10A cells notably increased proliferation compared to cells mock-transfected with empty vector. The equimolar co-transfection with SFRP2resulted in a decreased proliferation rate as compared to WNT1 alone. Furthermore, SFRP2-transfectants revealed a slightly reduced proliferation rate compared to cells containing empty vector. In order to support these findings we performed a colony formation assay and selected transfected clones for three weeks by the antibiotic G418. Representative results are shown in Figure 7B. Controls assured the feasibility of this assay, showing that wild type cells without G418 abundantly form colonies, whereas in the presence of G418 wild type cells fail to survive. SFRP2-transfected cells exhibit a reduced number of colonies as compared to mock-transfected cells. The difference in colony numbers from three independent experiments was statistically significant (P = 0.045, two-tailed Mann-Whitney U-test).
###end p 68
###begin p 69
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 inhibits proliferation in breast epithelial cells</bold>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1</italic>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1</italic>
###xml 435 441 435 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 473 479 473 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1 </italic>
###xml 587 593 587 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 620 625 620 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1 </italic>
###xml 803 808 803 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 1090 1095 1090 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 1130 1132 1130 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
SFRP2 inhibits proliferation in breast epithelial cells. (A) MCF10A cells transfected with empty vector (Mock), SFRP2-expression vector, WNT1-expression vector or a combination of SFRP2+WNT1-expression vectors were subjected to XTT proliferation assays. At three subsequent time points, optical densities (OD) of the supernatants were measured. RNA Expression of the respective genes was surveyed in parallel 4 days post transfection. GAPDH served as cDNA loading control. SFRP2 was able to reduce a proliferative effect mediated by WNT1 overexpression, whereas the inhibiting effect of SFRP2 on cells not stimulated by WNT1 was only marginal (HA). (B) Long-term inhibiting effects of SFRP2 on the ability to form colonies in MCF10A cells. Cells were either transfected with empty vector (Mock) or with SFRP2-expression vector, and after 3 weeks of selective pressure (antibiotic G418) fixed, stained and photographed. Non-transfected wild type cells (WT) are shown as controls with (+) and without (-) the application of G418. The difference in colony numbers between mock-transfected and SFRP2-transfected cells is significant (P = 0.045; two-tailed Mann-Whitney U-test).
###end p 69
###begin title 70
Discussion
###end title 70
###begin p 71
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 740 746 740 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP1 </italic>
###xml 750 756 750 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP5 </italic>
###xml 917 919 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 920 922 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 974 980 974 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 148 153 <span type="species:ncbi:9606">human</span>
###xml 685 690 <span type="species:ncbi:9606">human</span>
###xml 898 905 <span type="species:ncbi:9606">patient</span>
###xml 1021 1026 <span type="species:ncbi:9606">human</span>
Aberrant methylation of CpG islands in gene promoters has been ascertained as a primary mechanism for the inactivation of tumor suppressor genes in human malignancies, including colon and breast cancer (for review see [3]). Clinically, the identification of genes that are prone to abnormal methylation and consequently become downregulated is of critical importance since this is considered to provide a good source of novel tumor biomarkers [52] and potential targets for chemotherapeutics [53,54]. The family of SFRP genes, functionally acting as Wnt signaling inhibitors, was recently shown to be a common target of promoter hypermethylation in numerous tumor entities [19-26]. In human breast cancer, we have previously shown that the SFRP1 and SFRP5 promoter is epigenetically silenced in 61% and 73% of invasive breast carcinomas, respectively, each of which was associated with unfavorable patient prognosis [27,28]. We here demonstrate that promoter methylation of SFRP2 is a further tumor-related alteration in human breast cancer occurring with even higher incidence.
###end p 71
###begin p 72
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 139 145 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 186 192 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 294 300 294 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 491 497 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 719 725 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 902 908 902 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
Initiating our study, we found that many breast cancer cell lines revealed abolished SFRP2 expression presumably due to methylation of the SFRP2 promoter, since those cell lines lacking SFRP2 methylation abundantly expressed SFRP2 mRNA, whereas all cell lines lacking SFRP2 expression harbored SFRP2 promoter methylation. A direct coherence between promoter methylation and loss of RNA expression was shown by a combined DAC/TSA treatment of breast cancer cell lines, demonstrating that the SFRP2 gene was effectively demethylated and re-expressed after the treatment. Furthermore, those cell lines revealed a significant reduction of cyclin D1 expression, suggesting reactivation of anti-proliferative genes, of which SFRP2 is supposed to be a member [19,23,24]. Interestingly, in partially methylated SKBR3 and T47D cells the sole inhibition of histone deacetylases by TSA led to restoration of some SFRP2 expression, indicating that besides DNA methylation in these cells further reversible chromatin repressing histone modifications may exist.
###end p 72
###begin p 73
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo </italic>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 416 422 416 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 492 498 492 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 650 656 650 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 918 924 918 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1041 1048 1041 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 1107 1108 1103 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 380 386 <span type="species:ncbi:8164">Suzuki</span>
Since cell lines may acquire de novo genetic and epigenetic lesions during cultivation [55,56] it is mandatory to investigate such aberrations in primary tissues as well. To this end we analyzed SFRP2 promoter methylation in 199 infiltrating breast carcinomas by MSP. We found a high-frequent incidence of SFRP2 methylation in the tumors (83%), confirming the recent results from Suzuki et al. [37], who reported of SFRP2 methylation in 60 of 78 (77%) primary breast carcinomas. Importantly, SFRP2 methylation was independent of relevant clinicopathological factors, thus being unlikely related to disease stage or a molecular breast cancer subtype. SFRP2 methylation was equally prevalent in small sized (pT1) and in larger sized (pT2-4) breast carcinomas, suggesting it occurs as early epigenetic aberration in breast tumorigenesis with no further increase in methylation frequency during tumor progression. Whether SFRP2 methylation is already present in benign and earlier premalignant lesions such as atypical hyperplasia and carcinoma in situ, like it was recently reported for the 14-3-3-sigma gene [9], will be of particular importance in regard of early breast tumor detection. Yet, this remains to be determined in a future study.
###end p 73
###begin p 74
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 30 32 30 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 233 239 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 518 521 518 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 732 737 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 757 765 757 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 989 995 989 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUNX3 </italic>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1033 1041 1033 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 1129 1135 1129 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1233 1239 1233 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1365 1371 1365 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1637 1639 1637 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1669 1675 1669 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1763 1765 1763 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1839 1841 1839 1841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1866 1868 1866 1868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1892 1898 1892 1898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1998 2004 1998 2004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 2119 2121 2119 2121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 2156 2158 2156 2158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 15 21 <span type="species:ncbi:8164">Suzuki</span>
###xml 2333 2341 <span type="species:ncbi:9606">patients</span>
Interestingly, Suzuki et al. [37] reported that a certain number of cancer-related normal breast tissues also showed weak SFRP2 methylation in their study, whereas in our study none of the normal breast tissues harbored a methylated SFRP2 promoter, irrespective of whether the tissue was taken from matched cancer-related or unmatched cancer-unrelated specimens. Given that no contaminating tumor cells had been present in their normal breast tissues this might be due to different locations of the recruited tissues (i.e. distance to the tumor margin), and may address a phenomenon that in cancer research is currently being discussed as "field defect" [57,58]. Evidence of such field defect in breast cancer was brought up by Yan et al. [59] showing that RASSF1A promoter methylation in breast carcinoma may progressively diffuse outwards to surrounding normal tissue, establishing a sphere of methylation gradient around the primary tumor. Recently, such gradient was also detected for RUNX3 methylation [60], which together with RASSF1A methylation is among the earliest carcinogenetic events in breast tumor transformation. SFRP2 methylation may be implicated in such field defect in breast cancer, yet dense methylation of the SFRP2 promoter was restricted to carcinoma in our study, and thus it may display important clinical specificity. In bladder cancer, SFRP2 methylation was shown to represent an independent predictor of malignancy, although in multivariate logistic regression analysis it was not a reliable biomarker because of a limited sensitivity/specificity due to some extent of methylation in normal bladder mucosa [22]. In contrast, in faecal DNA SFRP2 methylation was proven to be a highly promising screening marker for colorectal cancer [34], even potent to detect early lesions like adenoma, aberrant crypt foci [35] and colorectal polyps [36] due to the absence of SFRP2 methylation in normal colonic mucosa. In breast cancer, the accurate specificity and sensitivity of SFRP2 methylation remains to be determined by quantitative methods in a future study, for instance by qMSP (MethyLight) [61] or the Pyrosequencing technique [62], integrating receiver-operating characteristic (ROC) curve analyses. This may potentially lead to a valuable early tumor detection marker that will ideally be assessable in patients' body fluids like blood serum, plasma or nipple aspirate.
###end p 74
###begin p 75
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 567 573 567 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 647 653 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 746 752 746 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 953 959 953 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1064 1070 1064 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 1095 1100 1095 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 1526 1528 1526 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1540 1542 1540 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1543 1545 1543 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1581 1583 1581 1583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 2081 2087 2081 2087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 2201 2207 2201 2207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 2367 2369 2367 2369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 2498 2501 2498 2501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 337 342 <span type="species:ncbi:9606">human</span>
###xml 656 661 <span type="species:ncbi:9606">human</span>
###xml 807 812 <span type="species:ncbi:9606">human</span>
###xml 853 858 <span type="species:ncbi:9606">human</span>
###xml 922 927 <span type="species:ncbi:9606">human</span>
###xml 1193 1198 <span type="species:ncbi:9606">human</span>
###xml 1426 1433 <span type="species:ncbi:9606">patient</span>
###xml 1512 1517 <span type="species:ncbi:9606">human</span>
###xml 1646 1651 <span type="species:ncbi:9606">human</span>
###xml 2157 2162 <span type="species:ncbi:9606">human</span>
Contrasting the view that SFRP2 acts as a tumor suppressor gene, Lee and co-workers [42,63] suggested that SFRP2 exhibits rather an oncogenic property in breast tissue since this group detected strong upregulation of SFRP2 protein in canine mammary tumors relative to normal canine breast tissues. In addition, SFRP2 overexpression in a human breast cancer cell line (MCF7) inhibited apoptosis following UV light exposure, while increasing cell-substrate adhesion capacity [64]. It is worthy to note that these experiments were carried out with a canine homologue of SFRP2 cDNA. However, five lines of evidence propose a tumor suppressive role of SFRP2 in human breast carcinogenesis: (1.) Our and another independent study [37] demonstrate that SFRP2 is very frequently targeted by promoter methylation in human breast carcinomas as compared to normal human breast tissues, disposing breast cancer to the large number of human tumor entities for which SFRP2 methylation has already been described. (2.) We found a strong correlation and functional association of SFRP2 methylation with loss of SFRP2 mRNA expression in breast cell lines. (3.) Our study reveals a common SFRP2 protein loss in human breast carcinomas with comparable frequency to promoter methylation, notably by applying the identical SFRP2-antibody that was used for the study of canine mammary tumors. (4.) We detected a weak trend towards adverse clinical patient outcome in case of SFRP2 protein expression loss. (5.) Functional analyses in human breast [37], gastric [23,24] and colorectal cancer cell lines [19] revealed a pro-apoptotic and anti-proliferative capacity of (human) SFRP2 associated with the ability to inhibit activated Wnt signaling, altogether supporting a tumor suppressive rather than an oncogenic function of this gene. These discrepancies to canine mammary tumors may reflect subtle distinctions in the function of structurally related molecules, or alternative activities of molecules when expressed in different contexts and organisms. Furthermore, it emphasizes that study results of SFRP2 from canine breast cancer models may not be generally transferable to human breast carcinogenesis. In conclusion, SFRP2 may represent a candidate class II tumor suppressor gene whose altered expression is caused by epigenetic changes (class II) rather than by mutation (class I) [65]. Class II tumor suppressor genes are particularly interesting drug targets since reversing the block of their gene expression, e.g. by DNA methyltransferase (DNMT) inhibitors or histone deacetylase (HDAC) inhibitors could lead to tumor regression. Furthermore such a treatment could be appropriate to eliminate minimal residual cancer disease after surgical resection of the tumor.
###end p 75
###begin p 76
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 589 594 <span type="species:ncbi:9606">human</span>
Summarizing, our data demonstrate that SFRP2 is a frequent target of epigenetic inactivation in human breast cancer leading to downregulation of SFRP2 expression in mammary tumors. Loss of SFRP2 expression confers a growth advantage to mammary cells, likely due its ability to inhibit oncogenic Wnt signaling. Altogether, our data support the proposed tumor suppressive function of SFRP2 in normal breast tissue. The high incidence and the putative specificity of this epimutation may qualify SFRP2 methylation as potential candidate in a screening marker panel for the early detection of human breast cancer.
###end p 76
###begin title 77
Conclusion
###end title 77
###begin p 78
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 247 253 247 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 507 513 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP1 </italic>
###xml 516 522 516 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP5 </italic>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 931 937 931 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 22 27 <span type="species:ncbi:9606">human</span>
Our study on SFRP2 in human breast cancer leads to the following conclusions: SFRP2 expression is very frequently downregulated in breast cancer due to promoter methylation, thus conferring growth advantage to neoplastic mammary cells. Therefore, SFRP2 may be assigned a class II tumor suppressor gene in normal breast tissue, whose block of expression could be reversed by DNA demethylating (DNMT inhibitors) and histone reacetylating (HDAC inhibitors) drugs. In contrast to an adverse prognostic value of SFRP1 or SFRP5 methylation in breast cancer, failure of SFRP2 methylation as a prognostic biomarker may be explained by redundant functions of these closely related SFRP molecules. Alternatively, this failure could be explained by the likely involvement of SFRP2 methylation in the early steps of breast carcinogenesis, rather than being implicated in the development of prognostically adverse tumor subtypes. Nevertheless, SFRP2 methylation may be potentially useful as a molecular tumor biomarker in a DNA methylation biomarker based screening assay, as it may display high clinical sensitivity and specificity in detecting breast cancer cells.
###end p 78
###begin title 79
Competing interests
###end title 79
###begin p 80
The authors declare that they have no competing interests.
###end p 80
###begin title 81
Authors' contributions
###end title 81
###begin p 82
###xml 130 139 130 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 476 482 476 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
JV participated in the design of the study, carried out the RNA expression and methylation analyses, immunohistochemical studies, in vitro experiments, statistical analysis, and wrote the manuscript. EN performed realtime expression analysis, assisted in Pyrosequencing and data interpretation, and critically revised the manuscript. NB participated in immunohistochemical analysis and data interpretation, and critically revised the manuscript. EJ designed and optimized the SFRP2 Pyrosequencing assay, and critically revised the manuscript. AH participated in collection of clinical data, performed data interpretation, and critically revised the manuscript. RK participated in the design and coordination of the study, and critically revised the manuscript. ED planned and coordinated the study, and critically revised the manuscript. All authors have read and approved the final version of the manuscript.
###end p 82
###begin title 83
Supplementary Material
###end title 83
###begin title 84
Additional file 1
###end title 84
###begin p 85
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Clinicopathological and immunohistochemical characteristics of primary invasive breast carcinomas (n = 199).</bold>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 194 201 <span type="species:ncbi:9606">patient</span>
Clinicopathological and immunohistochemical characteristics of primary invasive breast carcinomas (n = 199). The data provided represent the relevant clinicopathological and immunohistochemical patient characteristics used in SFRP2 methylation analysis.
###end p 85
###begin p 86
Click here for file
###end p 86
###begin title 87
Additional file 2
###end title 87
###begin p 88
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Primer sequences and cycle conditions used in this study.</bold>
Primer sequences and cycle conditions used in this study. This table provides oligonucleotide primer sequences and PCR cycle conditions that were used throughout this study.
###end p 88
###begin p 89
Click here for file
###end p 89
###begin title 90
Acknowledgements
###end title 90
###begin p 91
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2</italic>
###xml 505 510 505 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WNT1 </italic>
###xml 315 322 <span type="species:ncbi:9606">patient</span>
###xml 551 557 <span type="species:ncbi:8164">Suzuki</span>
###xml 654 659 <span type="species:ncbi:9606">Human</span>
The expert technical help of Sevim Alkaya, Sonja von Serenyi and Inge Losen is greatly appreciated. We thank Dr. Dieter Niederacher (Department of Gynecology and Obstetrics, Heinrich-Heine-University, Dusseldorf, Germany) and Prof. Matthias Durst (Friedrich-Schiller University, Jena, Germany) for kindly providing patient samples. We are thankful to Dr. Monika Klinkhammer-Schalke and Monika Kerscher from the Tumor Registry Regensburg for continuous help in obtaining clinical follow-up data. The SFRP2/WNT1 vectors were a kind gift from Dr. Hiromu Suzuki (Sapporo Medical University, Sapporo, Japan). This work is a research project within the German Human Genome Project and has been supported by the grant from the Bundesministerium fur Bildung und Forschung to Edgar Dahl (01KW0401).
###end p 91
###begin article-title 92
Gene silencing in cancer in association with promoter hypermethylation
###end article-title 92
###begin article-title 93
Aberrant DNA methylation as a cancer-inducing mechanism
###end article-title 93
###begin article-title 94
DNA methylation in breast and colorectal cancers
###end article-title 94
###begin article-title 95
###xml 109 114 <span type="species:ncbi:9606">human</span>
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
###end article-title 95
###begin article-title 96
###xml 99 104 <span type="species:ncbi:9606">human</span>
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
###end article-title 96
###begin article-title 97
###xml 61 66 <span type="species:ncbi:9606">human</span>
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
###end article-title 97
###begin article-title 98
Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype
###end article-title 98
###begin article-title 99
The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation
###end article-title 99
###begin article-title 100
Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer
###end article-title 100
###begin article-title 101
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort
###end article-title 101
###begin article-title 102
Secreted Frizzled-related proteins: searching for relationships and patterns
###end article-title 102
###begin article-title 103
Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling
###end article-title 103
###begin article-title 104
Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow
###end article-title 104
###begin article-title 105
Wnt signaling and cancer
###end article-title 105
###begin article-title 106
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients
###end article-title 106
###begin article-title 107
Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC
###end article-title 107
###begin article-title 108
Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression
###end article-title 108
###begin article-title 109
beta-Catenin and p53 analyses of a breast carcinoma tissue microarray
###end article-title 109
###begin article-title 110
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
###end article-title 110
###begin article-title 111
###xml 84 89 <span type="species:ncbi:9606">human</span>
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma
###end article-title 111
###begin article-title 112
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA
###end article-title 112
###begin article-title 113
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection
###end article-title 113
###begin article-title 114
###xml 107 112 <span type="species:ncbi:9606">human</span>
Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer
###end article-title 114
###begin article-title 115
Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer
###end article-title 115
###begin article-title 116
Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma
###end article-title 116
###begin article-title 117
###xml 46 51 <span type="species:ncbi:9606">human</span>
Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma
###end article-title 117
###begin article-title 118
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
###end article-title 118
###begin article-title 119
###xml 83 88 <span type="species:ncbi:9606">human</span>
Epigenetic inactivation of the Secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis
###end article-title 119
###begin article-title 120
###xml 94 99 <span type="species:ncbi:9606">human</span>
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer
###end article-title 120
###begin article-title 121
Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus
###end article-title 121
###begin article-title 122
Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer
###end article-title 122
###begin article-title 123
Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer
###end article-title 123
###begin article-title 124
Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor
###end article-title 124
###begin article-title 125
Methylation changes in faecal DNA: a marker for colorectal cancer screening?
###end article-title 125
###begin article-title 126
Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions
###end article-title 126
###begin article-title 127
SFRP2 methylation in fecal DNA-a marker for colorectal polyps
###end article-title 127
###begin article-title 128
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer
###end article-title 128
###begin article-title 129
Method for grading breast cancer
###end article-title 129
###begin article-title 130
Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue
###end article-title 130
###begin article-title 131
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer
###end article-title 131
###begin article-title 132
Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine mammary gland tumors but not in normal mammary glands
###end article-title 132
###begin article-title 133
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 133
###begin article-title 134
Methylation-specific polymerase chain reaction
###end article-title 134
###begin article-title 135
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia
###end article-title 135
###begin article-title 136
###xml 11 19 <span type="species:ncbi:274808">Searcher</span>
CpG Island Searcher
###end article-title 136
###begin article-title 137
Ensembl Genome Browser
###end article-title 137
###begin article-title 138
###xml 41 46 <span type="species:ncbi:9606">human</span>
Comprehensive analysis of CpG islands in human chromosomes 21 and 22
###end article-title 138
###begin article-title 139
MethPrimer: designing primers for methylation PCRs
###end article-title 139
###begin article-title 140
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
###end article-title 140
###begin article-title 141
###xml 45 50 <span type="species:ncbi:9606">human</span>
Cyclin D1 protein expression and function in human breast cancer
###end article-title 141
###begin article-title 142
The power and the promise of DNA methylation markers
###end article-title 142
###begin article-title 143
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies
###end article-title 143
###begin article-title 144
###xml 15 20 <span type="species:ncbi:9606">human</span>
Epigenetics in human disease and prospects for epigenetic therapy
###end article-title 144
###begin article-title 145
###xml 35 40 <span type="species:ncbi:9606">human</span>
Biological differences among MCF-7 human breast cancer cell lines from different laboratories
###end article-title 145
###begin article-title 146
###xml 26 31 <span type="species:ncbi:9606">human</span>
Comparison of features of human breast cancer cell lines and their corresponding tumors
###end article-title 146
###begin article-title 147
MGMT promoter methylation and field defect in sporadic colorectal cancer
###end article-title 147
###begin article-title 148
###xml 43 62 <span type="species:ncbi:210">Helicobacter pylori</span>
High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk
###end article-title 148
###begin article-title 149
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue
###end article-title 149
###begin article-title 150
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome
###end article-title 150
###begin article-title 151
DNA methylation analysis by MethyLight technology
###end article-title 151
###begin article-title 152
Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites
###end article-title 152
###begin article-title 153
Secreted Frizzled Related Protein 2 (sFRP2) Decreases Susceptibility to UV-Induced Apoptosis in Primary Culture of Canine Mammary Gland Tumors by NF-kappaB Activation or JNK Suppression
###end article-title 153
###begin article-title 154
Autocrine/paracrine secreted Frizzled-related protein 2 induces cellular resistance to apoptosis: a possible mechanism of mammary tumorigenesis
###end article-title 154
###begin article-title 155
Tumor suppressor genes: the puzzle and the promise
###end article-title 155

